Pfizer's Talzenna plus Xtandi approved earlier for advanced prostate cancer with certain gene changes
Published
The FDA cleared the pill combination for men with metastatic prostate cancer and HRR gene mutations whose cancer still responds to hormone therapy. In a 599-patient trial, adding Talzenna cut the risk of the cancer worsening or death by 52%. A genetic test is needed to qualify, so ask your oncologist about testing.
Source: CURE
This is a plain-language summary. Read the original source for full details.